We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. OK, I agree | Cookies Policy

Gastroenterology

0

Congresses: Noventure participates at the second edition of IBS Days

Noventure, as part of its ongoing activities in support of the launch of Gelsectan®, participated with a stand at the IBS Days 2018 in Bologne, Italy, May 17 - 19, 2018.   This meeting is intended to provide current views and a look to the future on the rapidly advancing field of IBS. One of the lectures was devoted to mucosal barrier and permeability, which is a hot topic among gastroenterologists specialized in IBS management.  Gelsectan® contains mucoprotectors which improve the resistance of the mucosal barrier and help restore its normal function.  It is intended to relieve and prevent IBS symptoms such as chronic or relapsing diarrhoea, pain and bloating.

Read more

Noventure presents its pediatric range at the 51st ESPGHAN Annual Meeting in Geneva, 09-12 May 2018

As in previous years, Noventure has participated in the ESPGHAN Congress, held in Geneva, 09-12 May 2018. Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to GI conditions in children. 4.627 delegates from 100 countries participated at the congress, and many of them approached Noventure´s stand to request information. Our innovative products intended for acute diarrhea (TASECTAN®, TASECTAN DUO® and XILAPLUS®) attracted a lot of interest from doctors.

Read more

Noventure expands the commercialization of GELSECTAN® across Europe through new partnerships

Noventure is proud to announce new agreements for the distribution of its medical device GELSECTAN® with Klinge (Germany), Tramedico (Benelux), Montavit (Austria), Galenica (Greece, Romania Bulgaria and Cyprus), Lapidot (Israel) and Sabora (Finland). These partnerships come after the successful partnership with Norgine in Spain and Portugal, where GELSECTAN® is already on the market. Irritable bowel syndrome is a burdensome disease which has an estimated global prevalence of more than 10%, predominantly affecting adults, especially women, of working age.

Read more

Let's meet in..

2018, Aug 29

FNM 2018

FNM-2018-Amsterdam
Read more

2018, Oct 09

CPHI

Read more

2018, Oct 24

UEG Week 2018

Read more

2018, Nov 26

EuroPLX 68

Read more

2018, Nov 29

PharmaVenue November 2018

Read more